HomeIvantis Inc

Ivantis Inc

Hydrus® Microstent Device for Minimally Invasive Glaucoma Surgery Receives FDA Approval

8/13/18: The FDA approval is based on the landmark HORIZON Trial, the largest MIGS study ever conducted. The study included 556 mild to moderate glaucoma patients undergoing cataract surgery, randomized to either receive cataract surgery plus the Hydrus Microstent (treatment) or cataract surgery alone (control).